Company News: J&J nixes production of heart stent, Sanofi pairs with Audion

Share this article:

Johnson & Johnson company Cordis has announced that it will discontinue the development of the Nevo Sirolimus-Eluting Coronary Stent in order to focus on other cardiovascular therapies that are more in patient demand. Cordis will also halt production of Cypher and Cypher Select Plus Sirolimus-Eluting Coronary Stents by the end of 2011, according to a release.

Recently rebranded big pharma Sanofi has announced a two-year research partnership with biopharma company Audion Therapeutics with the objective of developing potential treatments for hearing loss. The collaboration will utilize technology developed at the Massachusetts Eye and Ear Infirmary – one of the world's leading research facilities devoted to the study of hearing and deafness – for the optimization of small molecules by using a regenerative medicine approach.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions